Attached files
file | filename |
---|---|
EX-10.8 - EX-10.8 - ALSERES PHARMACEUTICALS INC /DE | b82691exv10w8.htm |
EX-10.7 - EX-10.7 - ALSERES PHARMACEUTICALS INC /DE | b82691exv10w7.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 10, 2010
ALSERES PHARMACEUTICALS, INC.
Delaware | 0-6533 | 87-0277826 | ||
(State or Other Juris- diction of Incorporation |
(Commission File Number) |
(IRS Employer Identification No.) |
239 South Street, Hopkinton, Massachusetts | 01748 | |
(Address of Principal Executive Offices) | (Zip Code) |
Registrants telephone number, including area code: (508) 497-2360
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions ( see General
Instruction A.2. below):
o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 1.01. | Entry into Material Definitive Agreements. |
On September 10, 2010, Alseres Pharmaceuticals, Inc. (the Company), entered into a Note
Purchase Agreement (the Agreement) with Highbridge International LLC (the Seller) and Robert
Gipson Pursuant to which the Company agreed to purchase from the Seller, effective on September 14,
2010, a Convertible Promissory Note issued on May 2, 2007 to the Seller in the principal amount of
$5,880,000 for an aggregate purchase price equal to $602,700 payable in immediately available
federal funds by the Company to the Seller. In a related transaction, on September 13, 2010 the
Company issued to Robert L. Gipson (the Holder) an unsecured promissory note, pursuant to which
the Company borrowed an aggregate principal amount of $700,000 (the Note). Interest on the Note
shall accrue at the rate of 7% per annum and all principal and accrued interest shall be due and
payable on demand of the Holder.
The foregoing description of the Agreement and the Note are qualified in their entirety by the
full text of the Agreement and the Note, complete copies of each are filed herewith as Exhibits
10.7 and 10.8 respectively and each is incorporated herein by reference.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Alseres Pharmaceuticals, Inc. |
||||
Date: September 16, 2010 | By: | /s/ Kenneth L. Rice, Jr. | ||
Kenneth L. Rice, Jr. | ||||
Executive Vice President, Finance and Administration and Chief Financial Officer | ||||
-2-
EXHIBIT INDEX
Exhibit No. | Description | |||
10.7 | Note Purchase Agreement |
|||
10.8 | Promissory Note dated September 13, 2010 |
-3-